FormFactor (FORM) Q1 2026 Earnings Transcript

FormFactor reported Q1 revenue of $226.1 million, above the midpoint of guidance, with non-GAAP gross margin expanding 510 bps sequentially to 49% and non-GAAP EPS rising to $0.56. Management raised Q2 revenue guidance to $240 million (+/- $5 million) and expects 49.5% non-GAAP gross margin, while highlighting record DRAM probe card demand, growing networking/CPU exposure, and an accelerating Triton CPO ramp. The quarter also featured continued restructuring-led margin gains, $303 million of cash and investments, and no buybacks despite $70.9 million remaining under authorization.

Analysis

The key second-order read is that FORM is transitioning from a cyclical probe-card beneficiary into a structural share-gainer in HBM and AI-linked networking, while simultaneously proving it can monetize constrained capacity without relying on price. That matters because the earnings inflection is now coming from mix, yield, and throughput, not just end-demand, which usually extends the duration of margin expansion beyond what the market initially underwrites. The consequence is that the next leg up is more likely to be a multiple re-rate than a simple EPS beat, especially into the Investor Day catalyst.

The biggest hidden winners are the ecosystem names tied to advanced packaging and test infrastructure: the more HBM density rises and CPO moves from lab to production, the more validation steps get inserted, not removed. That creates a longer runway for TER and potentially TSM-adjacent packaging spend, while INTC is a smaller but meaningful sentiment beneficiary if its CPU/foundry turnaround continues to pull through probe demand. NVDA benefits indirectly via better supply-chain readiness, but FORM’s mix shift suggests the bottleneck is now test capacity and qualification, not chip demand, which is a subtle bullish signal for the whole AI hardware stack.

The main risk is that the market extrapolates near-term operating leverage too far ahead of Farmers Branch. That facility is a 2027 story, not a 2026 revenue fix, so any disappointment in incremental output gains over the next two quarters could compress the stock if investors start treating current run-rate margins as permanent. Tariff treatment is another latent swing factor: if refunds are recognized, reported economics improve; if not, Q2/Q3 may look less “clean” than the headline margin suggests.

Consensus likely underestimates how much of the current setup is supply-side optionality rather than demand strength. If the company can keep adding $10M-$15M quarterly revenue through utilization gains before the new site ramps, the market may have to chase a higher base EPS power into year-end. The asymmetry is favorable, but the trade should respect that the easy re-rating often happens before the investor-day narrative is fully digested, and the stock could be vulnerable to a classic post-event pause if expectations become too linear.

Key Decisions for Investors

• Long FORM into the May 11 Investor Day with a 4-8 week horizon; use any post-event consolidation to add, because the next target model can re-anchor the multiple if management credibly lifts the medium-term margin/capacity path.
• Pair trade: long FORM / short TER on a 2-3 month view if you want to isolate AI test intensity; FORM has the cleaner near-term margin inflection and capacity leverage, while TER is more exposed to slower semiconductor capital spending normalization.
• Buy FORM Jan-2027 call spreads to express the 2027 Farmers Branch option value with defined downside; the setup is favorable if utilization gains persist, but the facility ramp is too far out for outright stock-only convexity.
• If already long NVDA or TSM, consider adding FORM as a lower-beta supply-chain beneficiary rather than chasing the mega-cap names; FORM offers a more direct sensitivity to HBM/CPO test intensity and can outperform if qualification cycles stay tight.
• Avoid shorting on the current beat/re-raise pattern unless there is evidence of decelerating quarterly utilization gains; the cleaner contrarian short is only after the market prices in perfect execution ahead of the new target model.